Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Biomarin Pharmaceuticals
(NQ:
BMRN
)
70.10
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Biomarin Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
7 Biotech Stocks Fighting America’s Deadliest Diseases
February 08, 2024
Although the human condition can be alarmingly frail at times, these groundbreaking biotech stocks are aiming to right the ship.
Via
InvestorPlace
3 No-Brainer Stocks to Buy With $200 Right Now
February 07, 2024
A reasonably small amount of money can go a long way when it's put to work in innovative, industry-leading businesses.
Via
The Motley Fool
Decoding 8 Analyst Evaluations For Biomarin Pharmaceutical
January 30, 2024
Via
Benzinga
4 Marvelous Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
January 20, 2024
A greater than 7% decline in the Nasdaq Composite from its record high signals that opportunistic investors can still find bargains.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
If You Can Only Buy One Biotech Stock in January, It Better Be One of These 3 Names
January 10, 2024
Biotech is one of the areas of interest in the market today, adding a biotech stock could be huge play this month.
Via
InvestorPlace
Cracking The Code: Understanding Analyst Reviews For Biomarin Pharmaceutical
December 21, 2023
Via
Benzinga
Earnings Outlook For Biomarin Pharmaceutical
October 31, 2023
Via
Benzinga
15 Analysts Have This to Say About Biomarin Pharmaceutical
October 16, 2023
Via
Benzinga
What 16 Analyst Ratings Have To Say About Biomarin Pharmaceutical
September 13, 2023
Via
Benzinga
4 Preeminent Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
December 02, 2023
An 11% decline in the Nasdaq Composite over the past two years is an open invitation for opportunistic growth investors to go shopping.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
Under the Microscope: 3 Biotech Stocks Pioneering Tomorrow’s Cures
November 09, 2023
Unveil the resilience of biotech stocks as they outsmart market trends and champion the race for tomorrow's treatments.
Via
InvestorPlace
3 Promising Biotech Stocks Flying Under the Radar
November 08, 2023
Breakthroughs in healthcare are happening everyday, make sure you are keeping up to date on these under the radar biotech stocks.
Via
InvestorPlace
BioMarin Surges As Activist Investor Elliott Reportedly Builds $1 Billion Stake
November 07, 2023
The company's recently FDA-approved gene therapy is struggling to gain traction.
Via
Investor's Business Daily
Datadog, Tripadvisor, Myriad Genetics, Planet Fitness And Other Big Stocks Moving Higher On Tuesday
November 07, 2023
U.S. stocks traded mostly higher, with the Nasdaq Composite gaining around 50 points on Tuesday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Earnings Outlook For Biomarin Pharmaceutical
July 28, 2023
Via
Benzinga
4 Unique Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
November 04, 2023
A 19% decline in the Nasdaq Composite over the past two years represents an ideal time for opportunistic long-term investors to go shopping for bargains.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
Why Is Gene Therapy Player PTC Therapeutics Stock Plunging Today?
October 27, 2023
In its Q3 earnings release, PTC Therapeutics Inc (NASDAQ: PTCT) reported a
Via
Benzinga
3 Under-the-Radar Biotech Stocks to Buy in 2023
October 19, 2023
These three lesser-known biotech companies are profitable and growing revenue.
Via
The Motley Fool
Impact on BioMarin's Sentiment: Voxzogo's Triumph Clouded by Uncertainty
September 28, 2023
Raymond James initiated coverage on BioMarin Pharmaceuticals Inc (NASDAQ: BMRN) with a Market Perform rating, noting sparsity in
Via
Benzinga
Are Gene Therapy Stocks The Market's Next Big Winners?
September 25, 2023
Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price.
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
What 9 Analyst Ratings Have To Say About Biomarin Pharmaceutical
July 27, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 28, 2023
September 28, 2023
Via
Benzinga
4 Awe-Inspiring Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
September 23, 2023
A nearly 15% decline in the growth-driven Nasdaq Composite from its record high is a blessing in disguise for opportunistic long-term investors.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
Benzinga's Top Ratings Upgrades, Downgrades For September 18, 2023
September 18, 2023
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
September 15, 2023
Via
Benzinga
Have Million-Dollar Gene Therapies Finally Reached An Inflection Point?
September 15, 2023
Gene therapies are clearing the FDA and reaching seriously ill patients. They could cost millions.
Via
Investor's Business Daily
Exposures
Product Safety
4 Preeminent Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
September 02, 2023
The innovation-fueled Nasdaq Composite remains 13% below its all-time high, which means bargains can still be found.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
4 Unforgettable Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
August 12, 2023
With the growth-driven Nasdaq Composite still 14% below its record-closing high, deals abound.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
Biomarin's Q2 Beat Street View, Raises Voxzogo Annual Guidance Driven By Global Demand
August 01, 2023
Biomarin Pharmaceutical Inc (NASDAQ: BMRN) reported a Q2 adjusted EPS of $0.54, higher than $0.41 a year ago and beating the
Via
Benzinga
Earnings Scheduled For July 31, 2023
July 31, 2023
Companies Reporting Before The Bell • Immunogen (NASDAQ:IMGN) is estimated to report quarterly loss at $0.16 per share on revenue of $42.84 million.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.